key: cord-1008466-62oxt3kj authors: Liszka, Karolina; Marschollek, Pawel; Gul, Katarzyna; Musial, Jakub; Chaber, Radoslaw; Miskiewicz-Bujna, Justyna; Mlynarski, Wojciech; Kalwak, Krzysztof title: Successful salvage haploidentical bone marrow transplantation in a child with hemophagocytic lymphohistiocytosis, when the previously matched unrelated donor tested positive for SARS-CoV-2 on the day of stem cells collection. date: 2021-04-27 journal: Transplant Proc DOI: 10.1016/j.transproceed.2021.04.017 sha: a10b775976215324502c17c88df95f51ccd2818a doc_id: 1008466 cord_uid: 62oxt3kj COVID-19 pandemic makes us adjust our standards and cope with unpredictable circumstances affecting the whole world around, including the medical field. A 2-year-old boy diagnosed with X-linked Lymphoproliferative Disease Type 2 (XLP2) with concomitant positive PCR test for EBV-DNA was admitted to our transplant ward. His treatment scheme had to be modified at the last moment, because of a donor disqualification due to a positive PCR result for SARS-CoV2 just before the apheresis. We decided to perform salvage haploidentical bone marrow transplant from the patient's mother as it was the only possible option. Now, in a five-month observation period after the HSCT, our patient is in a good general condition. His case convinced us to redirect our approach to transplant procedure preparation. Following the European Group of Blood and Marrow Transplantation (EBMT) recommendations, we use cryopreserved apheresis materials to ensure the availability of stem cells products before the start of a conditioning regimen. Worldwide outbreak of the COVID-19 pandemic forces us to face new challenges not only in the field of managing patients with SARS-CoV2 infection, but also in dealing with other medical problems in the new -COVID reality. We are made to redirect our approach to treatment in many branches of medicine and adjust our standards. A haemophagocytic lymphohistiocytosis (HLH) is a life-threatening systemic, hyperinflammatory syndrome. Its clinical manifestations include: acute unremitting fever, lymphadenopathy, hepatosplenomegaly, and multiorgan failure. Due to a massive cytokine release, it is recognised as a cytokine storm syndrome, which requires aggressive immunosuppressive treatment. Even though, we know more and more about its pathogenesis, diagnosis and management, there is still plenty to discover. HLH can be classified as primary, when it is caused by some gene defects (PRF1, UNC13D, STXBP2, STX11, RAB27A, LYST, AP3B1, SH2D1A and XIAP/BIRC4) or secondary, when it is acquired, triggered by factors such as: infection, malignancy, autoimmune disease or post-allogeneic hematopoietic stem cell transplantation (HSCT) [1] . X-linked lymphoproliferative disorder (XLP) is especially challenging for physicians, because of its complex medical manifestation. It is considered as a primary immune deficiency syndrome with clinical presentation of HLH and special vulnerability to Epstein-Barr virus (EBV) infection. An impaired immune system and insufficient number of CD27 memory B cells make it difficult to generate an effective response to EBV, so the infection may be chronic and lead to severe complications such as bone marrow failure, irreversible hepatitis or lymphoma. Although the exact connection between EBV and XLP disorder is not yet well established. It is possible that EBV infection triggers HLH not only in secondary forms of syndrome, but also in its familial types. To distinguish the kind of disorder presenting with the same clinical manifestation, it is vital to obtain a molecular diagnosis. It is recommended to aim at allogeneic haematopoietic stem cell transplantation (HSCT) in genetically verified or familial types of disease -[2, Fig.1 ]. Here, we present a very actual problem in the COVID19 pandemic era, namely how to rescue a patient when MUD tested positive for SARS-CoV-2 on the day of stem cell collection and the patient has almost finished his conditioning regimen. The primary manifestation of XLP2 in our patient was HLH, which was treated with dexamethasone monotherapy acc. to national coordinator's recommendations. As the patient had positive PCR test for EBV-DNA, it led to a hypothesis that EBV infection was a trigger in his case. Nevertheless, according to HLH-2004, he fulfilled criteria and was planned for HSCT after achievement of controllable disease [2] . HLA During the five-month observation period after the HSCT, as we regularly see the patient in our outpatient clinic, he has been in a good general condition and with full donor chimerism in PB. The only concern was associated with the development of cytomegalovirus reactivation in February 2021, which was successfully treated with valganciclovir p.o. Shortly before then, in January 2021 our patient developed catheter-related bloodstream infection and Proteus mirabilis was grown in culture. The boy recovered quickly after central line removal and antibiotics implementation. Although our patient went home in a good medical state, clinical trials' results on haploidentical HSCT in HLH patients encourage us to withhold excessive optimism. A study of 86 children treated with HLH-94 protocol followed by HSCT presented similar long-term disease-free survival (70% at 3 years) with matched unrelated donor transplants as with matched sibling transplants. On the other hand, survival with family haploidentical donor transplants or mismatched unrelated transplants showed much less favourable results with long-term disease-free survival of 50% only [7] . Other clinical reports suggest that haploidentical HSCT with PTCY is a reasonable option for children with HLH lacking a matched sibling donor [8] . Although was not lower in haploidentical transplantations. Interestingly, this study does not support the preference of matched unrelated donor when a haploidentical donor is easily available [9] . Nowadays, when the list of indications for HSCT extends at a quick pace, the donor availability is the limiting factor that needs to be broadened. New GvHD prophylactic treatment options such as PTCY and other supportive methods in HSCT regimens should be intensively investigated to further improve the availability of donor sources [10] . As there is an increased risk of graft rejection in patients with HLH, we decided to use full marrow with PTCY and not in-vitro T-cell depleted PBSCs. The use of ATG during conditioning regimen in patients undergoing HSCT with PTCY might increase the risk of aGvHD, which was observed in our case. The same ATG proved to be a curative option in steroid-and multidrug-refractory GvHD, which occurred in our patient. With extended anti-GvHD armamentarium in our hands we feel safer even in lifethreatening salvage procedures during COVID19 pandemic. Bearing in mind the whole patient's medical history and the circumstances, in which we were placed, the HSCT treatment with haploidentical donor was not optimal for that boy, but it was salvage and the only possible option then. The European Society on Blood and Marrow Transplantation (EMBT) recommendations on secured stem cells product access has been changed recently, as the COVID-19 pandemic situation has altered since summer 2020. Freezing of products is no longer the advised procedure, because there were several reports of cryopreserved products never infused. On the other hand, the emergence of a new SARS-CoV2 strains in the UK and in the Republic of South Africa along with consecutive new travel restrictions, arouses the threat of donor availability and increases the need for cryopreservation again [11] . This case has convinced us to change our policy of donor procurement and collection logistics. Since the above mentioned transplant we have used only cryopreserved apheresis materials from matched unrelated donors (MUDs) to ensure the availability of stem cells products before the start of a conditioning regimen. Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer Strategy of pre-emptive management of Epstein-Barr virus post-transplant lymphoproliferative disorder after stem cell transplantation: results of European transplant centers survey T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors Graft-versus-host disease Prevention of graft versus host disease by inactivation of host antigen-presenting cells Bone marrow transplantation in hemophagocytic lymphohistiocytosis Successful Haploidentical Stem Cell Transplant With Posttransplant Cyclophosphamide for Hemophagocytic Lymphohistiocytosis Sequential Conditioning with Thiotepa in T Cell-Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors Recent progress in haploidentical transplantation: is this the optimal choice for alternative donor transplantation? EBMT RECOMMENDATIONS VERSION 15 -February The authors declare no conflict of interests. The only source of support was Wroclaw Medical University statutory grant ST.C200.18.013.